• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

    11/14/24 4:16:31 PM ET
    $MYGN
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $MYGN alert in real time by email
    SC 13G/A 1 sc13ga_no2_mygn.htm SC 13G/A 1 sayw24021425_13ga.htm


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549



    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 2)*

    Myriad Genetics, Inc.
    (Name of Issuer)

    Common Stock, $0.01 par value per share
    (Title of Class of Securities)

    62855J104
    (CUSIP Number)

    September 30, 2024
    (Date of Event which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

       ☐
    Rule 13d-1(b)
       ☒
    Rule 13d-1(c)
       ☐
    Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

    Continued on following pages
    Page 1 of 9 Pages
    Exhibit Index: Page 7


    CUSIP No. 62855J104
    Page 2 of 9 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    GLENVIEW CAPITAL MANAGEMENT, LLC
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Delaware
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    1,261,530
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    1,261,530
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,261,530
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    1.39%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    OO
     
     
     
     


    CUSIP No. 62855J104
    Page 3 of 9 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    LARRY ROBBINS
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    United States of America
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    1,261,530
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    1,261,530
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    1,261,530
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    1.39%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IN, HC
     
     
     
     


    CUSIP No. 62855J104
    Page 4 of 9 Pages
    Item 1(a).
    Name of Issuer:

    Myriad Genetics, Inc. (the “Issuer”)

    Item 1(b).
    Address of Issuer’s Principal Executive Offices:

    322 North 2200 West, Salt Lake City, UT 84116

    Item 2(a).
    Name of Person Filing:

    This Statement is filed on behalf of each of the following persons (collectively, the “Reporting Persons”):

      i)
    Glenview Capital Management, LLC (“Glenview Capital Management”); and
      ii)
    Larry Robbins (“Mr. Robbins”).

    This Statement relates to Shares (as defined herein) held for the accounts of Glenview Capital Master Fund, Ltd., a Cayman Islands exempted company (“Glenview Capital Master Fund”), Glenview Offshore Opportunity Master Fund, Ltd., a Cayman Islands exempted company (“Glenview Offshore Opportunity Master Fund”), and Glenview Healthcare Master Fund, L.P., a Cayman Islands limited partnership (“Glenview Healthcare Master Fund” and collectively, the “Glenview Funds”).

    Glenview Capital Management serves as investment manager to each of the Glenview Funds. Mr. Robbins is the Chief Executive Officer of Glenview Capital Management.

    Item 2(b).
    Address of Principal Business Office or, if None, Residence:

    The address of the principal business office of each of Glenview Capital Management and Mr. Robbins is 767 Fifth Avenue, 44th Floor, New York, New York 10153.

    Item 2(c).
    Citizenship:

     
    i)
    Glenview Capital Management is a Delaware limited liability company;
     
    ii)
    Mr. Robbins is a citizen of the United States of America.

    Item 2(d).
    Title of Class of Securities:

    Common Stock, $0.01 par value per share (the “Shares”)

    Item 2(e).
    CUSIP Number:

    62855J104

    Item 3.
    If This Statement is Filed Pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), Check Whether the Person Filing is a:

    This Item 3 is not applicable.


    CUSIP No. 62855J104
    Page 5 of 9 Pages
    Item 4.
    Ownership:

    Item 4(a).
    Amount Beneficially Owned:

    As of September 30, 2024, each of Glenview Capital Management and Mr. Robbins may be deemed the beneficial owner of 1,261,530 Shares. This amount consists of: (A) 619,836 Shares held for the account of Glenview Capital Master Fund; (B) 602,738 Shares held for the account of Glenview Offshore Opportunity Master Fund; and (C) 38,956 Shares held for the account of Glenview Healthcare Master Fund.

    Item 4(b).
    Percent of Class:

    As of September 30, 2024, each of the Reporting Persons may be deemed the beneficial owner of approximately 1.39% of Shares outstanding. (There were 90,820,354 Shares outstanding as of August 2, 2024, based on the Issuer’s quarterly report on Form 10-Q, filed on August 7, 2024.)

    Item 4(c).
    Number of Shares as to Which Such Person Has:

    Glenview Capital Management and Mr. Robbins:
    (i) Sole power to vote or direct the vote:
    0
    (ii) Shared power to vote or direct the vote:
    1,261,530
    (iii) Sole power to dispose or direct the disposition of:
    0
    (iv) Shared power to dispose or direct the disposition of:
    1,261,530

    Item 5.
    Ownership of Five Percent or Less of a Class:

    If this statement is being filed to report the fact that as of the date hereof each of the Reporting Persons has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person:

    See disclosure in Items 2 and 4 hereof. Certain funds listed in Item 2(a) are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the Shares covered by this Statement that may be deemed to be beneficially owned by the Reporting Persons.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person:

    See disclosure in Item 2 hereof.

    Item 8.
    Identification and Classification of Members of the Group:

    This Item 8 is not applicable.

    Item 9.
    Notice of Dissolution of Group:

    This Item 9 is not applicable.

    Item 10.
    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.


    CUSIP No. 62855J104
    Page 6 of 9 Pages
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    GLENVIEW CAPITAL MANAGEMENT, LLC
     
           
     
    By:
    /s/ Mark J. Horowitz
     
       
    Mark J. Horowitz
     
       
    Co-President of Glenview Capital Management, LLC
     
           
     
    LARRY ROBBINS
     
           
     
    By:
    /s/ Mark J. Horowitz
     
       
    Mark J. Horowitz, attorney-in-fact for Larry Robbins
     
           
    November 14, 2024
         


    CUSIP No. 62855J104
    Page 7 of 9 Pages
    EXHIBIT INDEX

    Ex.
    Page No.
    A
    Joint Filing Agreement
    8
    B
    Power of Attorney
    9


    CUSIP No. 62855J104
    Page 8 of 9 Pages
    EXHIBIT A

    JOINT FILING AGREEMENT

    The undersigned hereby agree that the statement on Schedule 13G with respect to the Common Stock of Myriad Genetics, Inc. dated as of November 14, 2024 is, and any amendments thereto (including amendments on Schedule 13D) signed by each of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.

     
    GLENVIEW CAPITAL MANAGEMENT, LLC
         
     
    By:
    /s/ Mark J. Horowitz
       
    Mark J. Horowitz
       
    Co-President of Glenview Capital Management, LLC
         
     
    LARRY ROBBINS
         
     
    By:
    /s/ Mark J. Horowitz
       
    Mark J. Horowitz, attorney-in-fact for Larry Robbins
         
    November 14, 2024
       


    CUSIP No. 62855J104
    Page 9 of 9 Pages
    EXHIBIT B

    POWER OF ATTORNEY

    KNOW ALL MEN BY THESE PRESENT, that I, Larry Robbins, hereby make, constitute and appoint Mark J. Horowitz, acting individually, as my agent and attorney-in-fact for the purpose of executing in my name, (a) in my personal capacity or (b) in my capacity as Chief Executive Officer or in other capacities of Glenview Capital Management, LLC, a Delaware limited liability company, and each of its affiliates or entities advised or controlled by me or Glenview Capital Management, LLC, all documents, certificates, instruments, statements, filings and agreements (“documents”) to be filed with or delivered to any foreign or domestic governmental or regulatory body or required or requested by any other person or entity pursuant to any legal or regulatory requirement relating to the acquisition, ownership, management or disposition of securities, futures contracts or other investments, and any other documents relating or ancillary thereto, including, without limitation, all documents relating to filings with the United States Securities and Exchange Commission (the “SEC”) pursuant to the Securities Act of 1933, as amended, or the Securities and Exchange Act of 1934, as amended (the “Act”), and the rules and regulations promulgated thereunder, including, without limitation: (1) all documents relating to the beneficial ownership of securities required to be filed with the SEC pursuant to Section 13(d) or Section 16(a) of the Act, including, without limitation: (a) any acquisition statements on Schedule 13D or Schedule 13G and any amendments thereto, (b) any joint filing agreements pursuant to Rule 13d-1(k), and (c) any initial statements of, or statements of changes in, beneficial ownership of securities on Form 3, Form 4 or Form 5 and (2) any information statements on Form 13F required to be filed with the SEC pursuant to Section 13(f) of the Act.

    All past acts of the attorney-in-fact in furtherance of the foregoing are hereby ratified and confirmed.

    This Power of Attorney revokes the previous Power of Attorney, executed by the undersigned on February 10, 2009, and shall remain in effect until revoked, in writing, by the undersigned.

    IN WITNESS WHEREOF, the undersigned has executed this Power of Attorney, this 2nd day of February, 2016.

    /s/ Larry Robbins

    Larry Robbins



    Get the next $MYGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MYGN

    DatePrice TargetRatingAnalyst
    5/8/2025Outperform → Peer Perform
    Wolfe Research
    5/7/2025$6.00Overweight → Equal Weight
    Wells Fargo
    4/9/2025Buy → Neutral
    Guggenheim
    3/12/2025$11.50 → $12.50Neutral → Overweight
    Piper Sandler
    2/12/2025$29.00Buy
    Craig Hallum
    12/10/2024$18.00Neutral
    UBS
    12/9/2024$30.00 → $21.00Outperform → Market Perform
    Leerink Partners
    9/19/2024$32.00Equal-Weight
    Morgan Stanley
    More analyst ratings

    $MYGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Myriad Genetics Announces RiskScore Study Published in JCO Precision Oncology

      SALT LAKE CITY, May 07, 2025 (GLOBE NEWSWIRE) --  Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, announced today that JCO Precision Oncology published a real-world study suggesting that the results of RiskScore® led clinicians to recommend breast cancer screening aligned with patients' individual risk. RiskScore, Myriad's clinically validated breast cancer risk assessment tool integrated into its MyRisk® Hereditary Cancer Test, combines a polygenic risk score (PRS) validated for all ancestries with the widely-used Tyrer-Cuzick model to predict five-year and remaining lifetime risk of breast cancer. The study, "Association of Polygenic

      5/7/25 4:30:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Concerns about Mental Health Medication Side Effects Remain a Barrier to Getting Help for Those Diagnosed with Depression and Anxiety, According to the GeneSight Mental Health Monitor

      SALT LAKE CITY, April 30, 2025 (GLOBE NEWSWIRE) -- Nearly nine out of ten (89%) Americans diagnosed with depression and/or anxiety believe mental health medications are somewhat or very effective, yet concerns about potential side effects remain a significant barrier, preventing more than half (52%) from taking medication, according to the latest GeneSight® Mental Health Monitor, a nationwide survey from Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine. The majority of these patients (54%) agree that genetic testing for mental health medications (known as pharmacogenomic or PGx testing) could reduce these concerns. "It's encouraging to

      4/30/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Commerical Officer Donnelly Brian J was granted 397,534 shares (SEC Form 4)

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/2/25 4:15:16 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 3 filed by new insider Donnelly Brian J

      3 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:29:48 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Chief Operating Officer Verratti Mark

      4 - MYRIAD GENETICS INC (0000899923) (Issuer)

      5/1/25 4:27:14 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Myriad Genetics downgraded by Wolfe Research

      Wolfe Research downgraded Myriad Genetics from Outperform to Peer Perform

      5/8/25 8:27:12 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Wells Fargo with a new price target

      Wells Fargo downgraded Myriad Genetics from Overweight to Equal Weight and set a new price target of $6.00

      5/7/25 8:36:31 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics downgraded by Guggenheim

      Guggenheim downgraded Myriad Genetics from Buy to Neutral

      4/9/25 8:36:07 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    SEC Filings

    See more
    • SEC Form 10-Q filed by Myriad Genetics Inc.

      10-Q - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 8:48:53 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - MYRIAD GENETICS INC (0000899923) (Filer)

      5/6/25 4:08:36 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form S-8 filed by Myriad Genetics Inc.

      S-8 - MYRIAD GENETICS INC (0000899923) (Filer)

      5/1/25 4:03:06 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Financials

    Live finance-specific insights

    See more
    • Myriad Genetics Reports First Quarter 2025 Financial Results; Updates 2025 Financial Guidance

      Highlights First quarter 2025 revenue of $196 million declined by 3% year-over-year. Excluding headwinds1 of $16 million, revenue increased 5% year-over-year.First quarter 2025 Prenatal revenue grew 11% year-over-year, while Pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®. MyRisk®testing volume in the affected population grew 11% year-over-year. First quarter 2025 gross margin of 69% increased 40 basis points year-over-year, benefiting from greater laboratory efficiencies. First quarter 2025 GAAP net loss of $0.1 million, or $0.00 EPS, driven by $29 million tax benefit. Adjusted EPS was $(0.03) in the first quarter 2025.

      5/6/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics to Release First Quarter 2025 Financial Results on May 6, 2025

      SALT LAKE CITY, April 29, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostic testing and precision medicine, will hold its first quarter 2025 earnings conference call at 4:30 pm EDT on Tuesday, May 6, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the first quarter 2025. A live webcast of the conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon register

      4/29/25 9:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics to Release Fourth Quarter and Full Year 2024 Financial Results on February 24, 2025

      SALT LAKE CITY, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in genetic and genomic tumor testing and precision medicine, will hold its fourth quarter and full year 2024 earnings conference call at 4:30 pm ET on Monday, Feb. 24, 2025. The company's quarterly earnings will be released the same day after the market closes. During the call, Myriad management will provide a financial overview and business update of the company's performance for the fourth quarter and full year 2024. A live webcast of the earnings conference call can be accessed on Myriad's Investor Relations website at investor.myriad.com. To participate in the live conference call via telep

      2/18/25 8:30:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Myriad Genetics Inc.

      SC 13G/A - MYRIAD GENETICS INC (0000899923) (Subject)

      11/14/24 4:16:31 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Myriad Genetics Inc.

      SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

      5/1/24 4:21:33 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Myriad Genetics Inc.

      SC 13G - MYRIAD GENETICS INC (0000899923) (Subject)

      4/25/24 4:18:40 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $MYGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Myriad Genetics Names Brian Donnelly as New Chief Commercial Officer

      SALT LAKE CITY, April 07, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, announced today the appointment of Brian Donnelly as chief commercial officer (CCO), effective May 1, 2025. A strategic, results-oriented leader with more than 20 years of experience in healthcare, diagnostics, and medical technology, Donnelly has a proven track record of building and leading high-performing teams, managing multi-billion-dollar P&Ls, and driving growth through innovative go-to-market strategies. "Brian brings a unique combination of strategic vision and operational excellence, combined with a passion for patient-centric

      4/7/25 8:00:00 AM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Myriad Genetics Announces Senior Leadership Transition

      SALT LAKE CITY, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ:MYGN), a leader in molecular diagnostics testing and precision medicine, today announced that its Board of Directors has appointed Sam Raha, the Company's current Chief Operating Officer (COO), as President and Chief Executive Officer (CEO) and as a member of the Board, effective April 30, 2025. Mr. Raha will replace Paul J. Diaz, who is stepping down to join private equity firm Cressey & Company as a Managing Partner. Mr. Diaz will continue to serve the Company as a consultant to Mr. Raha and the Board of Directors for another year. "Since joining Myriad in December 2023, Sam has played an integral role in sh

      2/24/25 4:05:00 PM ET
      $MYGN
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Biote Announces CEO Retirement and Succession Plan

      Terry Weber Retiring as CEO and Director and Transitioning to Strategic Advisor to Company's Board of Directors Health Care Veteran Bret Christensen to Succeed Terry Weber as CEO and Director biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Terry Weber is retiring as Chief Executive Officer and stepping down from the Company's Board of Directors, effective as of February 1, 2025. She will be transitioning to Strategic Advisor to the Company's Board of Directors. Concurrently, Mr. Bret Christensen has been named Chief Executi

      1/30/25 4:10:00 PM ET
      $BTMD
      $HOLX
      $MYGN
      $PODD
      Medicinal Chemicals and Botanical Products
      Health Care
      Medical Electronics
      Biotechnology: In Vitro & In Vivo Diagnostic Substances